Showing 4101-4110 of 5771 results for "".
- Iveric Bio to Present Zimura GATHER2 Enrollment and Retention Updates and New GATHER1 Post-Hoc Analyseshttps://modernod.com/news/iveric-bio-to-present-zimura-gather2-enrollment-and-retention-updates-and-new-gather1-post-hoc-analyses/2479306/Iveric bio announced that today at the company’s Virtual Symposium for Investors and Analysts, Arshad M. Khanani, MD, MA, of Sierra Eye Associates, and Chairman of the GATHER2 Steering Committee, will discuss an accelerated enrollment timeline and patient retention, including injection fidelity,
- Santen to Host Dry Eye Disease Panel at Inaugural European Dry Eye Society Congress (EuDEC)https://modernod.com/news/santen-to-host-dry-eye-disease-panel-at-inaugural-european-dry-eye-society-congress-eudec/2479305/Santen EMEA announced it is taking place in the inaugural European Dry Eye Society Congress (EuDEC), which will be held virtually on June 18-19, 2021. Santen will host an international panel of experts for an online s
- Alcon’s ORA System Reaches 2 Million Caseshttps://modernod.com/news/alcons-ora-system-reaches-2-million-cases/2479303/Alcon announced its Optiwave Refractive Analysis (ORA) intraoperative aberrometer system has reached 2 million cases worldwide. This milestone signifies an important leap forward in cataract surgery by delivering greater accuracy than preoperative calculation methods alone. The ORA Syste
- Aerie Pharmaceuticals Completes Enrollment of its first Phase 3 Clinical Trial of Netarsudil Ophthalmic Solution in Japanhttps://modernod.com/news/aerie-pharmaceuticals-completes-enrollment-of-its-first-phase-3-clinical-trial-of-netarsudil-ophthalmic-solution-in-japan/2479300/Aerie Pharmaceuticals announced the completion of patient enrollment for its first phase 3 clinical trial of netarsudil ophthalmic solution in Japan, comparing netarsudil ophthalmic solution 0.02%, administered once a day in the evening, to ripasudil hydrochloride hydrate ophthalmic solution 0.4%
- The Retina Center, of Minneapolis and St. Paul, Joins Retina Consultants of Americahttps://modernod.com/news/the-retina-center-of-minneapolis-and-st-paul-joins-retina-consultants-of-america/2479299/Retina Consultants of America (RCA) announced that a 12th practice, The Retina Center, in Minneapolis and St. Paul, Minnesota, has joined RCA. The addition of The Retina Center expands RCA’s presence in Minnesota, as they join forces with RCA’s existing partner in the region, Vitreoret
- Market Scope: Ophthalmic Laser Market Expected to Total $376.4 Million in 2021https://modernod.com/news/market-scope-ophthalmic-laser-market-expected-to-total-376-4-million-in-2021/2479296/Global revenue for ophthalmic lasers—photocoagulation, photodisruption (YAG), and SLT—along with maintenance, accessories, and endoprobes, will total over $376.4 million in 2021 and grow at a compound annual rate of 2.4 percent from 2021 to 2026, according to Market Scope estimates. Factor
- Biogen Fails to Meet Primary or Secondary Endpoints in Phase 3 Gene Therapy Study in Choroideremiahttps://modernod.com/news/biogen-fails-to-meet-primary-or-secondary-endpoints-in-phase-3-gene-therapy-study-in-choroideremia/2479291/Biogen announced topline results from the phase 3 STAR study of timrepigene emparvovec (BIIB111/AAV2-REP1), an investigational gene therapy for the potential treatment of choroideremia. The STAR study did not meet its primary endpoint of proportion of participants with a ≥15 letter improvement fr
- Eyenovia Highlights Recent Progress in Three Phase 3 Programs, NDA Review Progress, and Licensing Agreementshttps://modernod.com/news/eyenovia-highlights-recent-progress-in-three-phase-3-programs-nda-review-progress-and-licensing-agreements/2479294/Eyenovia provided a corporate update on its pipeline with recent and upcoming milestones. Eyenovia previously announced initial topline data from its phase 3 VISION-1 clinical trial, which evaluated the company’s proprietary pilocarpine solution, administere
- Reed Exhibitions Unveils New Brand Identityhttps://modernod.com/news/reed-exhibitions-unveils-new-brand-identity/2479287/Reed Exhibitions announced its evolution to RX, with a refreshed visual identity and updated brand positioning, according to The Vision Council. Building on its flagship events business, the company is leveraging its capabilities in data and technology to create
- OcuGen to No Longer Pursue EUA for Covid-19 Vaccine Candidate Covaxin; Will Pursue Full Approvalhttps://modernod.com/news/ocugen-to-no-longer-pursue-eua-for-covid-19-vaccine-candidate-covaxin-will-pursue-full-approval/2479283/Ocugen announced that upon recommendation from the FDA, it will pursue submission of a biologics license application (BLA) for its COVID-19 vaccine candidate, Covaxin. The company will no longer pursue an Emergency Use Authorization (EUA) for Covaxin. The FDA provided feedback to Ocugen re